IL18 and COVID-19: SARS-CoV-2 infection could trigger the activation of NLRP3 inflammasome to release IL-1β, IL-18, and gasdermin D and, consequently, damage to lung tissue in patients with COVID-19, suggesting the dysregulation of NLRP3 inflammasome might contribute to the severity of COVID-19.